Savant Capital’s AnaptysBio ANAB Stock Holding History

Savant Capital’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$387K	Sell	5,736 -438	-7%	-$26.6K	﹤0.01%	1353
2026 Q1	$342K	Sell	6,174 -121	-2%	-$6.51K	﹤0.01%	1098
2025 Q4	$305K	Buy	+6,295	New	+$245K	﹤0.01%	1043

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Savant Capital's ANAB Position: Q2 2026 in Review

Savant Capital reduced its AnaptysBio (ANAB) stake by 7.1% in Q2 2026, selling an estimated $26.6K and leaving 5,736 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #1353.

Savant Capital first reported a position in ANAB in Q4 2025 and has held it in 3 quarters since. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Savant Capital held 5,736 shares of AnaptysBio worth $387K as of Q2 2026.
Savant Capital sold 438 AnaptysBio shares in Q2 2026, an estimated $26.6K.
AnaptysBio made up ﹤0.01% of Savant Capital's portfolio in Q2 2026, its #1353 holding.
Savant Capital first reported a position in AnaptysBio in Q4 2025 and has held it in 3 quarters since.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Savant Capital's 13F filing for Q2 2026, filed 10 Aug 2026.